Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2016 Feb 16;15(4):574–582. doi: 10.1158/1535-7163.MCT-15-0467

Figure 1. Identification of novel HdmX inhibitors.

Figure 1

A. Identification of novel compounds that induce a p21/ConA-β-gal reporter in MCF7 cells. MCF7 cells were treated for 24hr with the indicated compounds (2μM) and β-gal activity was measured. B. CTX1 and CTX6 exhibit p53-dependent activation of the reporter construct. MCF7 and MCF7shp53 cells were treated with the indicated compounds and β-gal activity was measured as described in fig1a. C. CTX1 and CTX6 induce p53 and p21. MCF7 cells were treated with CTX1 (2μM), CTX6 (3μM), or nutlin-3 (10μM) for 6hr and a western blot was performed. D. Structure of CTX1 and CTX1-biotin. Error bars represent standard deviation.